Compare MSA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSA | IBRX |
|---|---|---|
| Founded | 1914 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.2B |
| IPO Year | 1994 | 2015 |
| Metric | MSA | IBRX |
|---|---|---|
| Price | $186.36 | $7.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $197.40 | $12.57 |
| AVG Volume (30 Days) | 190.6K | ★ 7.0M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $1,874,814,000.00 | $113,288,000.00 |
| Revenue This Year | $6.78 | $88.59 |
| Revenue Next Year | $5.00 | $131.15 |
| P/E Ratio | $46.60 | ★ N/A |
| Revenue Growth | 3.69 | ★ 668.31 |
| 52 Week Low | $151.11 | $1.95 |
| 52 Week High | $208.92 | $12.43 |
| Indicator | MSA | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 52.42 |
| Support Level | $185.81 | $7.77 |
| Resistance Level | $192.41 | $8.51 |
| Average True Range (ATR) | 3.57 | 0.35 |
| MACD | -0.87 | 0.01 |
| Stochastic Oscillator | 16.10 | 41.92 |
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The company's product offerings include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems, among others. The end markets for its products include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. The company has organized its business into four geographical operating segments that are aggregated into two reportable segments: Americas and International. The majority of its revenue is generated from the Americas segment, which is comprised of the company's operations in Northern North America and Latin America geographies.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.